Novartis shares fall after cholesterol drug fails in study
Novartis shares fell 3.3% Monday morning after its cholesterol drug pelacarsen failed in a closely watched study, casting doubt on the approach. The failure raises the stakes for upcoming gene-therapy data.
Shares of Novartis BX:NOT fell 3.3% on Monday morning after its cholesterol drug failed in a closely watched study, casting doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker's upcoming data for a gene therapy.Late on Friday, Novartis said its drug pelacarsen did not c…